Pfizer Announces Topline Phase 3 Results For Sigvotatug Vedotin In Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer - R

• Sigvotatug Vedotin Does Not Improve Overall Survival Versus Docetaxel In Phase 3 Study • Sigvotatug Vedotin Shows Manageable Safety Profile Consistent With Prior Studies • No Clear IB6 Expression-Response Relationship Observed In Exploratory Analysis • Stronger Trend For OS And PFS With Sigvotatug Vedotin In Second-Line NSCLC Patients